Safety and efficacy of cryoballoon ablation for the treatment of atrial fibrillation in diabetic patients

Amr Abdin; Christian H. Heeger; Kivanc Yalin; Francesco Santoro; Natale Daniele Brunetti; Thomas Fink; Spyridon Liosis; Ben Brueggemann; Ahmad Keelani; Huong Lan Phan; Makoto Sano; Vanessa Sciacca; Evgeny Lyan; Dong An; Roza Meyer-Saraei; Feifan Ouyang; Karl Heinz Kuck; Charlotte Eitel; Julia Vogler; Roland Richard Tilz

doi:10.4022/JAFIB.2285

Safety and efficacy of cryoballoon ablation for the treatment of atrial fibrillation in diabetic patients

Amr Abdin, Christian H. Heeger, Kivanc Yalin, Francesco Santoro, Natale Daniele Brunetti, Thomas Fink, Spyridon Liosis, Ben Brueggemann, Ahmad Keelani, Huong Lan Phan, Makoto Sano, Vanessa Sciacca, Evgeny Lyan, Dong An, Roza Meyer-Saraei, Feifan Ouyang, Karl Heinz Kuck, Charlotte Eitel, Julia Vogler, Roland Richard Tilz^*

^*Corresponding author for this work

Clinic of Internal Medicine II - Cardiology

Abstract

Background: Cryoballoon based catheter ablation (CB-CA) is an established therapy for treatment of symptomatic atrial fibrillation (AF). However, data about AF ablation using the CB in the diabetic population is sparse. The aim of this single center retrospective study is to evaluate the safety and efficacy of CB ablation in patients with diabetes mellitus (DM) as compared to patients without DM. Methods and results: Between July 2015 and December 2017, 397 consecutive patients underwent CB-CA for AF. Forty-eight consecutive patients with DM (DM group, study group) were compared with propensity score-matched patients without DM (n=48, control group). All patients underwent pulmonary vein isolation (PVI) using the second-generation CB (CB2). The mean age in the DM group was 66.9±9.5 years and 69.5±8.8 in the non-DM group (p=0.18). During a follow-up of 12.7±5.1 months, single procedure success rate for the DM and the non-DM group was 68.7% and 70.8%, respectively (p=0.82). The most common complication was transient phrenic nerve palsy (4 DM group vs. 0 non-DM group, p=0.04). No severe complication such as procedure related deaths, atrio-esophageal fistula or cerebrovascular embolic events occurred. Conclusions: Our data strengthen the value of CB2 based ablation for the treatment of AF as an effective and safe procedure in DM patients, with similar success rates when compared with a non-DM population.

Original language	English
Journal	Journal of Atrial Fibrillation
Volume	12
Issue number	6
DOIs	https://doi.org/10.4022/JAFIB.2285
Publication status	Published - 2020

Funding

CHH received travel grants and research grants by Medtronic, Pfizer, Novartis, Claret Medical, SentreHeart, Biosense Webster, Boston Scientific and Cardiofocus. He received speaker’s honoraria from Cardiofocus, Boston Scientific and Novartis. RRT received travel grants from St. Jude Medical, Topera, Biosense Webster, Daiichi Sankyo, SentreHeart and speaker’s honoraria from Biosense Webster, Biotronik, Pfizer, Topera, Bristol-Myers Squibb; Bayer, Sano Aventis and research grants by Cardiofocus. CE received travel grants and educational grants by Medtronic. KHK received travel grants and research grants from Biosense Webster, Stereotaxis, Prorhythm, Medtronic, Edwards, Cryocath, and is a consultant to St. Jude Medical, Biosense Webster, Prorhythm, and Stereotaxis. He received speaker’s honoraria from Medtronic. All other authors have no relevant disclosures.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4022/JAFIB.2285

Cite this

Abdin, A., Heeger, C. H., Yalin, K., Santoro, F., Brunetti, N. D., Fink, T., Liosis, S., Brueggemann, B., Keelani, A., Phan, H. L., Sano, M., Sciacca, V., Lyan, E., An, D., Meyer-Saraei, R., Ouyang, F., Kuck, K. H., Eitel, C., Vogler, J., & Tilz, R. R. (2020). Safety and efficacy of cryoballoon ablation for the treatment of atrial fibrillation in diabetic patients. Journal of Atrial Fibrillation, 12(6). https://doi.org/10.4022/JAFIB.2285

@article{1cc3a33d31074cf5bc8f247f7db5be25,

title = "Safety and efficacy of cryoballoon ablation for the treatment of atrial fibrillation in diabetic patients",

abstract = "Background: Cryoballoon based catheter ablation (CB-CA) is an established therapy for treatment of symptomatic atrial fibrillation (AF). However, data about AF ablation using the CB in the diabetic population is sparse. The aim of this single center retrospective study is to evaluate the safety and efficacy of CB ablation in patients with diabetes mellitus (DM) as compared to patients without DM. Methods and results: Between July 2015 and December 2017, 397 consecutive patients underwent CB-CA for AF. Forty-eight consecutive patients with DM (DM group, study group) were compared with propensity score-matched patients without DM (n=48, control group). All patients underwent pulmonary vein isolation (PVI) using the second-generation CB (CB2). The mean age in the DM group was 66.9±9.5 years and 69.5±8.8 in the non-DM group (p=0.18). During a follow-up of 12.7±5.1 months, single procedure success rate for the DM and the non-DM group was 68.7\% and 70.8\%, respectively (p=0.82). The most common complication was transient phrenic nerve palsy (4 DM group vs. 0 non-DM group, p=0.04). No severe complication such as procedure related deaths, atrio-esophageal fistula or cerebrovascular embolic events occurred. Conclusions: Our data strengthen the value of CB2 based ablation for the treatment of AF as an effective and safe procedure in DM patients, with similar success rates when compared with a non-DM population.",

author = "Amr Abdin and Heeger, \{Christian H.\} and Kivanc Yalin and Francesco Santoro and Brunetti, \{Natale Daniele\} and Thomas Fink and Spyridon Liosis and Ben Brueggemann and Ahmad Keelani and Phan, \{Huong Lan\} and Makoto Sano and Vanessa Sciacca and Evgeny Lyan and Dong An and Roza Meyer-Saraei and Feifan Ouyang and Kuck, \{Karl Heinz\} and Charlotte Eitel and Julia Vogler and Tilz, \{Roland Richard\}",

note = "Funding Information: CHH received travel grants and research grants by Medtronic, Pfizer, Novartis, Claret Medical, SentreHeart, Biosense Webster, Boston Scientific and Cardiofocus. He received speaker{\textquoteright}s honoraria from Cardiofocus, Boston Scientific and Novartis. RRT received travel grants from St. Jude Medical, Topera, Biosense Webster, Daiichi Sankyo, SentreHeart and speaker{\textquoteright}s honoraria from Biosense Webster, Biotronik, Pfizer, Topera, Bristol-Myers Squibb; Bayer, Sano Aventis and research grants by Cardiofocus. CE received travel grants and educational grants by Medtronic. KHK received travel grants and research grants from Biosense Webster, Stereotaxis, Prorhythm, Medtronic, Edwards, Cryocath, and is a consultant to St. Jude Medical, Biosense Webster, Prorhythm, and Stereotaxis. He received speaker{\textquoteright}s honoraria from Medtronic. All other authors have no relevant disclosures. Publisher Copyright: {\textcopyright} 2020 CardioFront LLC. All rights reserved. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",

year = "2020",

doi = "10.4022/JAFIB.2285",

language = "English",

volume = "12",

journal = "Journal of Atrial Fibrillation",

issn = "1941-6911",

publisher = "CardioFront LLC",

number = "6",

}

Abdin, A, Heeger, CH, Yalin, K, Santoro, F, Brunetti, ND, Fink, T, Liosis, S, Brueggemann, B, Keelani, A, Phan, HL, Sano, M, Sciacca, V, Lyan, E, An, D, Meyer-Saraei, R, Ouyang, F, Kuck, KH, Eitel, C, Vogler, J & Tilz, RR 2020, 'Safety and efficacy of cryoballoon ablation for the treatment of atrial fibrillation in diabetic patients', Journal of Atrial Fibrillation, vol. 12, no. 6. https://doi.org/10.4022/JAFIB.2285

TY - JOUR

T1 - Safety and efficacy of cryoballoon ablation for the treatment of atrial fibrillation in diabetic patients

AU - Abdin, Amr

AU - Heeger, Christian H.

AU - Yalin, Kivanc

AU - Santoro, Francesco

AU - Brunetti, Natale Daniele

AU - Fink, Thomas

AU - Liosis, Spyridon

AU - Brueggemann, Ben

AU - Keelani, Ahmad

AU - Phan, Huong Lan

AU - Sano, Makoto

AU - Sciacca, Vanessa

AU - Lyan, Evgeny

AU - An, Dong

AU - Meyer-Saraei, Roza

AU - Ouyang, Feifan

AU - Kuck, Karl Heinz

AU - Eitel, Charlotte

AU - Vogler, Julia

AU - Tilz, Roland Richard

N1 - Funding Information: CHH received travel grants and research grants by Medtronic, Pfizer, Novartis, Claret Medical, SentreHeart, Biosense Webster, Boston Scientific and Cardiofocus. He received speaker’s honoraria from Cardiofocus, Boston Scientific and Novartis. RRT received travel grants from St. Jude Medical, Topera, Biosense Webster, Daiichi Sankyo, SentreHeart and speaker’s honoraria from Biosense Webster, Biotronik, Pfizer, Topera, Bristol-Myers Squibb; Bayer, Sano Aventis and research grants by Cardiofocus. CE received travel grants and educational grants by Medtronic. KHK received travel grants and research grants from Biosense Webster, Stereotaxis, Prorhythm, Medtronic, Edwards, Cryocath, and is a consultant to St. Jude Medical, Biosense Webster, Prorhythm, and Stereotaxis. He received speaker’s honoraria from Medtronic. All other authors have no relevant disclosures. Publisher Copyright: © 2020 CardioFront LLC. All rights reserved. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020

Y1 - 2020

N2 - Background: Cryoballoon based catheter ablation (CB-CA) is an established therapy for treatment of symptomatic atrial fibrillation (AF). However, data about AF ablation using the CB in the diabetic population is sparse. The aim of this single center retrospective study is to evaluate the safety and efficacy of CB ablation in patients with diabetes mellitus (DM) as compared to patients without DM. Methods and results: Between July 2015 and December 2017, 397 consecutive patients underwent CB-CA for AF. Forty-eight consecutive patients with DM (DM group, study group) were compared with propensity score-matched patients without DM (n=48, control group). All patients underwent pulmonary vein isolation (PVI) using the second-generation CB (CB2). The mean age in the DM group was 66.9±9.5 years and 69.5±8.8 in the non-DM group (p=0.18). During a follow-up of 12.7±5.1 months, single procedure success rate for the DM and the non-DM group was 68.7% and 70.8%, respectively (p=0.82). The most common complication was transient phrenic nerve palsy (4 DM group vs. 0 non-DM group, p=0.04). No severe complication such as procedure related deaths, atrio-esophageal fistula or cerebrovascular embolic events occurred. Conclusions: Our data strengthen the value of CB2 based ablation for the treatment of AF as an effective and safe procedure in DM patients, with similar success rates when compared with a non-DM population.

AB - Background: Cryoballoon based catheter ablation (CB-CA) is an established therapy for treatment of symptomatic atrial fibrillation (AF). However, data about AF ablation using the CB in the diabetic population is sparse. The aim of this single center retrospective study is to evaluate the safety and efficacy of CB ablation in patients with diabetes mellitus (DM) as compared to patients without DM. Methods and results: Between July 2015 and December 2017, 397 consecutive patients underwent CB-CA for AF. Forty-eight consecutive patients with DM (DM group, study group) were compared with propensity score-matched patients without DM (n=48, control group). All patients underwent pulmonary vein isolation (PVI) using the second-generation CB (CB2). The mean age in the DM group was 66.9±9.5 years and 69.5±8.8 in the non-DM group (p=0.18). During a follow-up of 12.7±5.1 months, single procedure success rate for the DM and the non-DM group was 68.7% and 70.8%, respectively (p=0.82). The most common complication was transient phrenic nerve palsy (4 DM group vs. 0 non-DM group, p=0.04). No severe complication such as procedure related deaths, atrio-esophageal fistula or cerebrovascular embolic events occurred. Conclusions: Our data strengthen the value of CB2 based ablation for the treatment of AF as an effective and safe procedure in DM patients, with similar success rates when compared with a non-DM population.

UR - https://www.scopus.com/pages/publications/85095770860

U2 - 10.4022/JAFIB.2285

DO - 10.4022/JAFIB.2285

M3 - Journal articles

AN - SCOPUS:85095770860

SN - 1941-6911

VL - 12

JO - Journal of Atrial Fibrillation

JF - Journal of Atrial Fibrillation

IS - 6

ER -

Safety and efficacy of cryoballoon ablation for the treatment of atrial fibrillation in diabetic patients

Abstract

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this